IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Merck, Sharpe & Dohme (Australia) Pty Ltd. v Genentech, Inc. [2014] APO 6
Patent Application: 2003287257
Title:Inhibition of IL-17 production
Patent Applicant: Genentech, Inc.
Opponent: Merck, Sharpe & Dohme (Australia) Pty Ltd.
Delegate: Dr B Akhurst
Decision Date: 6 February 2014
Hearing Date: 12 November 2013, in Canberra
Catchwords: PATENTS - section 59 opposition - novelty - lack of novelty by inevitable outcome - priority date deferred - lack of novelty over the specification intended for grant in Europe - inventive step - documents would not be ascertained - fair basis - no real and reasonably clear disclosure of a therapeutic method involving testing all subjects to determine they had elevated level of expression of IL-17 prior to treatment - grounds relating to manner of manufacture, useful, clarity, full description and claims define the invention not established
Representation: Patent applicant: Andrew Fox of Counsel, instructed by Dr Stuart Boyer of Griffith Hack, Perth.
Opponent: Matthew Darke of Counsel, instructed by Dr Andrew Blattman and Dr Simon Potter of Spruson & Ferguson, Sydney.
IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Patent Application: 2003287257
Title:Inhibition of IL-17 production
Patent Applicant: Genentech, Inc.
Date of Decision: 6 February 2014
DECISION
The opposition succeeds. The invention of claims 1-5, 11-12 and 14-33 lacks novelty. Claim 15 and all its dependent claims lack fair basis, insofar as these claims require each individual subject to be tested to determine an elevated level of IL-17 expression prior to treatment with the IL-23 antagonist.
Genentech is allowed 2 months from the date of this decision to file amendments to overcome the deficiencies in the claims.
Costs are awarded according to Schedule 8 against Genentech, Inc.
REASONS FOR DECISION
Background
Patent application 2003287257 was filed by Genentech, Inc. (Genentech) via the PCT on 29 October 2003 claiming priority from provisional application US 60/423,090 filed on 30 October 2002.
After examination, the application was advertised as accepted on 10 December 2009. Merck, Sharpe & Dohme (Australia) Pty Ltd. (MSDA) filed a notice of opposition on 10 March 2010 and served the statement of grounds and particulars on 10 June 2010. After extensions were granted for each evidentiary stage, evidence in support was completed on 29 September 2011, evidence in answer by 2 August 2012 and evidence in reply on 4 February 2013.
Evidence
The evidence in support of the opposition consists of declarations by:
· Andrew Nathaniel Blattman dated 28 July 2010 with Exhibits ANB-1 to ANB-36
· Stuart Graham Tangye dated 3 December 2010 (Tangye#1) with Exhibits SGT-1 to SGT-23
· Stuart Graham Tangye dated 28 June 2011 (Tangye#2) with exhibits SGT-24 to SGT-28
· Stuart Graham Tangye dated 28 September 2011 (Tangye#3)
The evidence in answer consists of declarations by:
· Stuart James Boyer dated 2 July 2012 with exhibits SJB-1 to SJB-14
· Stuart James Boyer dated 31 July 2012 with exhibits SJB-15 to SJB-19
· Wenjun Ouyang dated 7 March 2012 (Ouyang) with exhibits A to O
The evidence…
Keep reading for free
Create a free CaseChat account to read Merck, Sharpe & Dohme (Australia) Pty Ltd. v Genentech, Inc and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2014] APO 6
- Decision Date
CaseChat Overview and Summary
Orders
Orders of the court
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi